Clinical trials: Alcohol-associated Liver Disease
Liver Fibrosis Due to NASH, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Clinical Correlation Evaluation of the LIVERFASt Test for Diagnosing Important Liver Lesions of Fibrosis and Steatosis Against Magnetic Resonance Elastography (MRE) for Liver Fibrosis and MR-based Assessment of Steatosis, in Adult US Population.
This is a retrospective cross-sectional research intended to explore the utility of LIVERFASt in the clinical pathways for the detection of liver fibrosis and steatosis in comparison with the Magnetic Resonance Elastography (MRE)…
- Conditions
- Liver Fibrosis Due to NASH, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Alcohol Liver Disease
- Trial name
- LFMRECT (NCT06797596)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Fibronostics USA, Inc
Alcoholic Hepatitis
Utility of the Use of N-acetylcysteine Associated With Conventional Treatment in Patients With Severe Acute Alcoholic Hepatitis (Maddrey> 32)
This study is designed to evaluate the hypothesis that patients with severe acute alcoholic hepatitis have lower morbi-mortality if the patients receive treatment with corticosteroids + NAC, compared to patients that only receive…
- Trial name
- NCT05294744
- Testing
- N-acetylcysteine
- Where
- Spain
- Volunteers
- 390 people
- Sponsor
- Bioaraba Health Research Institute
Alcohol-associated Hepatitis
Integrated Therapies for Alcohol Use in Alcohol-associated Liver Disease (ITAALD) Trial
This is a multicenter, randomized, double-blinded, placebo-controlled trial focused on the treatment of severe alcohol-associated hepatitis (sAH) and alcohol use disorder (AUD).
- Trial name
- ITAALD (NCT07060638)
- Testing
- IL-22, Prednisone, Acamprosate
- Where
- 6 sites in United States
- Volunteers
- 216 people
- Sponsor
- Samer Gawrieh
Liver Disease; Alcohol-Related, Cirrhosis
Intestinal Microbiota Transplant in Alcohol-Associated Liver Disease
The purpose of this research study is to test the safety, tolerability, and effectiveness of the capsules that contain bacteria from healthy individuals when used to treat alcohol craving and drinking.
- Conditions
- Liver Disease; Alcohol-Related, Cirrhosis, Alcohol Use Disorder
- Trial name
- IMPACT (NCT05548452)
- Testing
- Intestinal Microbiota Transplant (IMT) Capsules
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Virginia Commonwealth University
Steatotic Liver Disease of Mixed Origin (MetALD)
Team Science (The Liver Health Study)
Liver damage from alcohol intake and weight-related behaviors is preventable and treatable only through lifestyle changes. This mixed-methods randomized controlled trial compares standard and enhanced approaches to screening…
- Trial name
- NCT06924281
- Testing
- Brief motivational interviewing with personalized feedback, Brief motivational interviewing with standard health information
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Brown University
Steatotic Liver Disease, MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
Long-term Follow-up to Determine Outcome in Liver Disease (LOVE Study)
The rational to conduct the LOVE study builds on the lack of available data on outcomes in steatotic liver disease in well characterized patients over a time frame of several years.
- Conditions
- Steatotic Liver Disease, MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis), Steatotic Liver Disease of Mixed Origin (MetALD), ALD - Alcoholic Liver Disease
- Trial name
- LOVE (NCT06907563)
- Where
- 4 sites in France, Germany and 2 more
- Volunteers
- 30,000 people
- Sponsor
- Universität des Saarlandes
Alcohol-related Liver Disease, Liver Diseases
Enhancing Alcohol Treatment Engagement in Associated Liver Disease (ALD) Patients
The purpose of this trial is to see if providing patients with alcohol-related liver disease with tailored alcohol use treatment options will increase engagement with treatment and correct possible misconceptions.
- Trial name
- ENGAGE-ALD (NCT06269510)
- Testing
- ENGAGE-ALD Application (APP), Treatment Facilitation bundle, Enhanced Usual Care
- Where
- United States
- Volunteers
- 268 people
- Sponsor
- Henry Ford Health System
Metabolic-dysfunction Associated Liver Disease (MASLD)
Testing a Multilevel, Culturally Appropriate Lifestyle Intervention For Hispanic Patients With Metabolic Dysfunction-associated Steatotic Liver Disease
The purpose of this study is to understand if a behavioral lifestyle intervention called the Healthy Liver/Hígado Sano program can help Hispanic/Latino patients with metabolic dysfunction associated steatotic liver disease…
- Trial name
- NCT07199491
- Testing
- Healthy Liver/Hígado Sano program, Usual Care
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- The University of Texas Health Science Center, Houston
Alcohol Use Disorder, Alcohol-associated Liver Disease
Pomegranate Dietary Supplements in AUD and ALD
The goal of this project is to determine an individual's ability to generate active gut microbial metabolites called urolithins upon consumption of pomegranate dietary supplements.
- Conditions
- Alcohol Use Disorder, Alcohol-associated Liver Disease, Alcoholic Cirrhosis, Healthy
- Trial name
- NCT07678567
- Testing
- Pomegranate Dietary Ssupplement
- Where
- United States
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- University of Louisville
Liver Transplant Recipient, Alcohol Use Disorders (AUD)
Intervention for Alcohol Use Disorder Recovery After Liver Transplantation
The goal of this clinical trial is to learn if it is feasible and acceptable to use a recovery coach and an online sober active community to help with alcohol use disorder after liver transplant.
- Trial name
- ILTARP (NCT07214259)
- Testing
- Online Sober Active Community, Recovery coach
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Leigh Anne Dageforde
Alcohol Use Disorder, Alcohol-associated Liver Disease
Implementation Facilitation Pilot for Alcohol Use Disorder (AUD) in Alcohol-associated Liver Disease (ALD)
The goal of this project is to improve provision of integrated medications for alcohol use disorder (MAUD) with brief counseling for patients with alcohol use disorder (AUD) and alcohol-associated liver disease (ALD) in…
- Trial name
- NCT07525258
- Testing
- Implementation Intervention
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Yale University
Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Alcohol-Related Liver Disease
A Large Language Model-based Chatbot for Alcohol Reduction in Patients With Metabolic Alcohol-Related Liver Disease
The goal of this pilot randomized controlled trial is to evaluate the trial feasibility and acceptability of LLM-based chatbot for reducing alcohol use among patients with metabolic alcohol-related liver disease.
- Trial name
- NCT07450144
- Testing
- LLM-based chatbot, Telephone counseling, Alcohol Brief Intervention
- Where
- Hong Kong
- Volunteers
- 50 people
- Sponsor
- The University of Hong Kong
Hepatitis
Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)
The primary purpose of this study is to evaluate the safety and efficacy of larsucosterol, as determined by transplant-free survival through Day 90 in participants with severe alcohol-associated hepatitis (AH) with pre-treatment…
- Trial name
- NCT07428538
- Testing
- Larsucosterol
- Where
- 92 sites in United States
- Volunteers
- 350 people
- Sponsor
- Bausch Health Americas, Inc.
MASLD
Phase II Study Evaluating the Efficacy and Safety of DR10624 Injection in MASLD and MetALD Subjects
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, Phase II clinical trial that consists of two parts.
- Trial name
- NCT07024212
- Testing
- DR10624 Injection
- Where
- 4 sites in China, Hong Kong
- Volunteers
- 110 people
- Sponsor
- Zhejiang Doer Biologics Co., Ltd.
Alcohol Use Disorder, Alcohol-associated Liver Disease
Financial Rewards for Reducing Alcohol Use in Patients With Liver Disease
This study tests whether providing financial rewards based on a blood test result can help people with alcohol-associated liver disease (ALD) stop or reduce their drinking.
- Conditions
- Alcohol Use Disorder, Alcohol-associated Liver Disease, Liver Cirrhosis, Alcoholic, Alcohol-Associated Hepatitis
- Trial name
- REINFORCE (NCT07465588)
- Testing
- PEth Based Contingency Management, PEth Monitoring with Fixed Incentives
- Volunteers
- 90 people
- Sponsor
- Massachusetts General Hospital
Acute Alcoholic Hepatitis, Chemical and Drug Induced Liver Injury
Digoxin In Treatment of Alcohol Associated Hepatitis
Prospective, single center, open label, randomized controlled trial to explore whether digoxin treatment affects cytokine levels as biomarkers of inflammation in patients with acute alcohol associated hepatitis, digoxin…
- Conditions
- Acute Alcoholic Hepatitis, Chemical and Drug Induced Liver Injury, Alcohol-Induced Disorders, Steatohepatitis Caused by Ingestible Alcohol
- Trial name
- DIGIT-AlcHep (NCT05014087)
- Testing
- Intravenous digoxin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Yale University
Alcohol-associated Liver Disease
RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in subjects with ALD.
- Trial name
- NCT07009860
- Testing
- Pemvidutide
- Where
- 37 sites in United States, Puerto Rico
- Volunteers
- 121 people
- Sponsor
- Altimmune, Inc.
Cirrhosis, End Stage Liver Disease
Mild Hypothermia and Acute Kidney Injury in Liver Transplantation
Acute kidney injury (AKI), or worsening kidney function, is a common complication after liver transplantation (20-90% in published studies).
- Conditions
- Cirrhosis, End Stage Liver Disease, Acute Kidney Injury, Liver Transplant; Complications
- Trial name
- MHALT (NCT03534141)
- Testing
- Esophageal cooling/warming device, Mild hypothermia, Normothermia
- Where
- 3 sites in United States
- Volunteers
- 175 people
- Sponsor
- University of California, San Francisco
Alcohol-associated Liver Disease
A Cross-sectional Study on the Association of Peptidoglycan Fragments Derived From Gut Microbiota With Alcohol Liver Disease
alcohol-associated liver disease (ALD) is a leading cause of cirrhosis, yet the role of gut microbiota-derived peptidoglycan (PG) metabolites in liver injury remains unclear.
- Trial name
- NCT07284862
- Testing
- An observational, non-interventional study design.
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Zhujiang Hospital
Alcohol Use Disorder, Alcohol Related Liver Disease
Peer Support for Liver Transplant Recipients With History of ALD
Liver transplant (LT) recipients with a history of alcohol-related liver disease (ALD) may encounter various psychosocial and medical challenges during post-LT recovery, even beyond the initial post-transplant period.
- Conditions
- Alcohol Use Disorder, Alcohol Related Liver Disease, Liver Transplant Recipient
- Trial name
- THRIVE (NCT07397598)
- Testing
- Peer Support
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- Johns Hopkins University